JP7428642B2 - 過剰増殖性疾患を処置するためのコーヒー酸誘導体 - Google Patents

過剰増殖性疾患を処置するためのコーヒー酸誘導体 Download PDF

Info

Publication number
JP7428642B2
JP7428642B2 JP2020525946A JP2020525946A JP7428642B2 JP 7428642 B2 JP7428642 B2 JP 7428642B2 JP 2020525946 A JP2020525946 A JP 2020525946A JP 2020525946 A JP2020525946 A JP 2020525946A JP 7428642 B2 JP7428642 B2 JP 7428642B2
Authority
JP
Japan
Prior art keywords
compound
groups
compound according
compounds
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020525946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502374A (ja
JP2021502374A5 (https=
Inventor
ヴァルデマー プリーベ
スタニスラフ スコラ
イザベラ フォクト
ラファウ ジエリンスキ
アルムガン ジャヤクマール
ラジェンジラネ ベヌゴパル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2021502374A publication Critical patent/JP2021502374A/ja
Publication of JP2021502374A5 publication Critical patent/JP2021502374A5/ja
Application granted granted Critical
Publication of JP7428642B2 publication Critical patent/JP7428642B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020525946A 2017-11-10 2018-11-09 過剰増殖性疾患を処置するためのコーヒー酸誘導体 Active JP7428642B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584591P 2017-11-10 2017-11-10
US62/584,591 2017-11-10
PCT/US2018/059975 WO2019094689A1 (en) 2017-11-10 2018-11-09 Caffeic acid derivatives for treating hyperproliferative diseases

Publications (3)

Publication Number Publication Date
JP2021502374A JP2021502374A (ja) 2021-01-28
JP2021502374A5 JP2021502374A5 (https=) 2021-12-16
JP7428642B2 true JP7428642B2 (ja) 2024-02-06

Family

ID=64664389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020525946A Active JP7428642B2 (ja) 2017-11-10 2018-11-09 過剰増殖性疾患を処置するためのコーヒー酸誘導体

Country Status (14)

Country Link
US (1) US10703721B2 (https=)
EP (1) EP3707125A1 (https=)
JP (1) JP7428642B2 (https=)
KR (1) KR20200085815A (https=)
CN (1) CN111417625A (https=)
AU (1) AU2018366270B2 (https=)
BR (1) BR112020009219A2 (https=)
CA (1) CA3081975A1 (https=)
EA (1) EA202091164A1 (https=)
MX (1) MX2020004871A (https=)
SG (1) SG11202004230XA (https=)
TW (1) TWI846678B (https=)
UA (1) UA126821C2 (https=)
WO (1) WO2019094689A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12539503B2 (en) 2022-08-03 2026-02-03 The University Of Toledo Environmentally friendly polymeric sorbent material for the extraction and determination of rare earth elements, thorium, and uranium

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068157A2 (en) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
JP2007515413A (ja) 2003-12-11 2007-06-14 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 細胞増殖性疾患を治療する化合
JP2011527679A (ja) 2008-07-08 2011-11-04 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム シグナル伝達性転写因子（ｓｔａｔ）の増殖及び活性化の新規の抑制剤
JP2013543490A (ja) 2010-09-24 2013-12-05 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
JP2016537316A (ja) 2013-10-10 2016-12-01 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
JP2017518287A (ja) 2014-06-02 2017-07-06 ファーマケア，インク． 脱ユビキチン化酵素阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
BRPI0709916B8 (pt) 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
WO2008005954A2 (en) 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
US20130129675A1 (en) 2009-12-04 2013-05-23 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
WO2015183987A1 (en) 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068157A2 (en) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
JP2007515413A (ja) 2003-12-11 2007-06-14 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 細胞増殖性疾患を治療する化合
JP2011527679A (ja) 2008-07-08 2011-11-04 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム シグナル伝達性転写因子（ｓｔａｔ）の増殖及び活性化の新規の抑制剤
JP2013543490A (ja) 2010-09-24 2013-12-05 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
JP2016537316A (ja) 2013-10-10 2016-12-01 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
JP2017518287A (ja) 2014-06-02 2017-07-06 ファーマケア，インク． 脱ユビキチン化酵素阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Peterson, Luke F.，Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies，Blood，2015年，125(23),，pp.3588-3597，DOI:10.1182/blood-2014-10- 605584.

Also Published As

Publication number Publication date
WO2019094689A1 (en) 2019-05-16
MX2020004871A (es) 2020-08-06
EP3707125A1 (en) 2020-09-16
JP2021502374A (ja) 2021-01-28
TWI846678B (zh) 2024-07-01
UA126821C2 (uk) 2023-02-08
CN111417625A (zh) 2020-07-14
AU2018366270A1 (en) 2020-05-21
KR20200085815A (ko) 2020-07-15
CA3081975A1 (en) 2019-05-16
AU2018366270B2 (en) 2023-04-20
TW201922707A (zh) 2019-06-16
US20190177276A1 (en) 2019-06-13
SG11202004230XA (en) 2020-06-29
BR112020009219A2 (pt) 2020-10-20
EA202091164A1 (ru) 2020-08-03
US10703721B2 (en) 2020-07-07

Similar Documents

Publication Publication Date Title
JP7105851B2 (ja) Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド
ES2533383T3 (es) Fármacos anticancerosos biodisponibles por vía oral relacionados con ácido cafeico
CN112020496B (zh) 作为rho激酶抑制剂的苯并吡唑类化合物
KR20200108078A (ko) Tnik 저해용 화합물 및 이들의 의약 용도
JP7428642B2 (ja) 過剰増殖性疾患を処置するためのコーヒー酸誘導体
JP5668092B2 (ja) 抗腫瘍薬としての５，６，又は７−置換−３−（ヘテロ）アリールイソキノリンアミン誘導体
AU2016353004A1 (en) Benzofuran derivatives for the treatment of CNS and other disorders
CN107072970A (zh) 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
WO2017223514A1 (en) Lxr inverse agonists for treatment of cancer
CN114805263A (zh) 3-(羟基苄基)苯酞类化合物、其制备方法和用途
CN105517996B (zh) 治疗活性化合物及其使用方法
CN113105409B (zh) 2-(羟基苄基)苯并[d]异噻唑酮类化合物、其制备方法和用途
KR102640385B1 (ko) 고혈압 및/또는 폐 섬유증 치료용 조성물
US10358439B2 (en) DNA binding agents with a minor groove binding tail
KR20260040160A (ko) Cyp11a1 억제제로서의 신규 화합물 및 그 용도
HK1259495B (en) Dna binding agents with a minor groove binding tail
BR122025013774A2 (pt) Compostos inibidores da via de sinalização notch, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos
HK1259495A1 (en) Dna binding agents with a minor groove binding tail

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200622

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230705

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240125

R150 Certificate of patent or registration of utility model

Ref document number: 7428642

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150